Why This Matters to Distributors: McKesson is locking in a major national pharmaceutical distribution relationship through June 2032, extending an agreement that otherwise would expire in 2027. The longer term gives McKesson greater visibility into a large customer relationship as it manages pharmaceutical inventory, transportation and distribution capacity, while underscoring the importance of multiyear agreements between major distributors and national accounts.
McKesson Corp. has reached an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032, securing a relationship that has lasted more than 25 years.
The Irving, Texas-based health care distributor said Oct. 1 that it will continue distributing pharmaceuticals to CVS Health’s mail-order and specialty pharmacies, retail pharmacies and distribution centers. The companies’ current agreement runs through June 2027, meaning the new agreement would extend the relationship another five years.
Financial terms were not disclosed. McKesson also did not announce any change in the scope of distribution services it provides CVS Health.
McKesson Chairman and CEO Brian Tyler said the extension reflects the companies’ long-standing relationship and their work to support pharmaceutical access. The agreement remains in principle, rather than a disclosed final long-form contract, according to McKesson’s announcement.
The extension is significant for McKesson because pharmaceutical distribution remains at the center of its business. Its North American Pharmaceutical segment includes the company’s U.S. and Canadian wholesale drug distribution operations, serving retail and community pharmacies and institutional health care providers.
McKesson said its pharmaceutical operations serve more than 40,000 customers across retail chains, independent pharmacies and institutional providers, including hospitals and health systems. The company has also continued to emphasize growth in specialty pharmaceutical distribution and services.
The CVS relationship spans several parts of the pharmacy company’s operations. McKesson’s agreement covers pharmaceutical deliveries not only to retail pharmacies but also to CVS Health’s specialty and mail-order pharmacies and distribution centers, giving the distributor a role across multiple points in the customer’s supply chain.
McKesson has extended the relationship before. In 2022, the companies agreed to continue their pharmaceutical distribution partnership through June 2027. The latest agreement would push that relationship into the next decade.
McKesson was not the only major pharmaceutical distributor to announce a CVS extension Oct. 1.
Cardinal Health separately said it entered into a binding letter of intent to extend its existing pharmaceutical distribution agreement with CVS Health through June 30, 2032. Cardinal said the agreement will continue the current scope of its distribution services.
The two announcements provide a broader view of CVS Health’s pharmaceutical supply strategy. Rather than waiting until the current agreements approach expiration, CVS is moving years in advance to continue relationships with two of the largest pharmaceutical distributors in the U.S.
For the distributors, the agreements provide greater visibility into important customer relationships through 2032. For CVS, they provide continuity in a pharmaceutical supply chain that supports retail stores, specialty operations, mail-order pharmacies and distribution facilities.
The McKesson and Cardinal agreements are separate, and neither distributor disclosed detailed pricing, volume commitments or other commercial terms. The announcements therefore do not establish how CVS divides pharmaceutical purchasing volume between the companies or whether that allocation will change under the extended agreements.
The extension comes as McKesson continues to reshape its portfolio around pharmaceutical distribution, specialty care, oncology and other health care services.
McKesson reorganized its reporting structure in fiscal 2026, creating a North American Pharmaceutical segment that combines its U.S. and Canadian wholesale drug distribution businesses. The company has said strengthening pharmaceutical distribution remains one of its strategic priorities.
At the same time, McKesson has been expanding further into specialty health care. In August, the company agreed to acquire Precision Medicine Group for approximately $2.25 billion, adding clinical research and biopharmaceutical commercialization capabilities to its Oncology and Multispecialty business.
McKesson is also preparing to separate its Medical-Surgical Solutions business into an independent company, Wellverse, in January 2027. That business distributes medical-surgical supplies, pharmaceuticals and laboratory equipment to physician offices, surgery centers, long-term care providers and other nonacute health care customers.
Those moves are narrowing McKesson’s strategic focus around pharmaceutical distribution and higher-growth specialty health care businesses. Against that backdrop, extending the CVS relationship protects continuity in McKesson’s core distribution operation while the company continues to reshape other parts of its portfolio.
The CVS agreement does not by itself indicate that McKesson will add distribution centers, inventory or transportation capacity. McKesson disclosed no related capital investment or network expansion in its Oct. 1 announcement.
What it does provide is a longer runway for a national account relationship that reaches across multiple CVS pharmacy channels. For a distributor operating a large, highly regulated pharmaceutical network, extending that relationship five years beyond its current expiration provides additional certainty as McKesson plans its network and investment priorities through the beginning of the next decade.
Do not miss any content from Distribution Strategy Group. Join our list.
Share this article:
